An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy

Trial Profile

An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 16 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Aug 2014, as per ClinicalTrials.gov record.
    • 13 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top